Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

New Antibiotic by Merck that Fights Bacteria

In the present drug discovery scenario, there are very few pharmaceutical companies who invest in research into antibiotics, as majority prefer to focus on profitable drugs for chronic diseases. Most drugs were developed 50 years ago and older antibiotics have lost their effect as the bacteria have become resistant to them.

Merck has developed an antibiotic – platensimycin, which could be used to fight bacteria such as MRSA, resistant to current antibiotics such as oxazolidinone and streptogrami. The antibiotic inhibits an enzyme called FabF, used in fatty acid formations that are building blocks of cell membranes and surfaces for bacteria.

The research team at Merck checked 250,000 natural compounds to discover potential antibacterials. Their research narrowed to platensimycin- a small bacterial molecule made by a bug in South Africa. The antibiotic has been tested on mice and did not have any toxic effect on them. The antibiotic still has to undergo various clinical phases before it can be made commercially viable.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024